Phathom Pharmaceuticals, Inc. 8-K

What Happened

• Phathom Pharmaceuticals, Inc. announced its financial results for the quarter and fiscal year ended December 31, 2025 via a press release dated February 26, 2026. The company furnished the press release as Exhibit 99.1 to a Current Report on Form 8-K (Item 2.02), which reports its results of operations and financial condition.

Key Details

• Filing date: February 26, 2026.
• Reporting period: quarter and year ended December 31, 2025.
• The press release announcing the results is attached as Exhibit 99.1 to the 8-K.
• The disclosure is furnished (not “filed”) under General Instruction B.2 to Form 8-K, meaning it is not subject to Section 18 liability and is not automatically incorporated by reference into other filings.

Why It Matters

• This 8-K is the company’s official public announcement of its latest earnings and financial condition—key information investors use to assess revenue, profitability (or losses), cash runway and quarterly results.
• Investors should read the attached press release for the specific financial metrics (revenue, net income or loss, operating expenses, cash position) and any management commentary or outlook that could affect the stock.
• Note the legal designation (furnished vs. filed) when considering reliance or incorporation of these disclosures into other SEC filings.